Premium
External‐beam radiotherapy for differentiated thyroid cancer locoregional control: A statement of the American Head and Neck Society
Author(s) -
Kiess Ana P.,
Agrawal Nishant,
Brierley James D.,
Duvvuri Umamaheswar,
Ferris Robert L.,
Genden Eric,
Wong Richard J.,
Tuttle R. Michael,
Lee Nancy Y.,
Randolph Gregory W.
Publication year - 2016
Publication title -
head and neck
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.012
H-Index - 127
eISSN - 1097-0347
pISSN - 1043-3074
DOI - 10.1002/hed.24357
Subject(s) - medicine , external beam radiotherapy , thyroid cancer , radiation therapy , head and neck cancer , radiology , surgery , thyroid , brachytherapy
The use of external‐beam radiotherapy (EBRT) in differentiated thyroid cancer (DTC) is debated because of a lack of prospective clinical data, but recent retrospective studies have reported benefits in selected patients. The Endocrine Surgery Committee of the American Head and Neck Society provides 4 recommendations regarding EBRT for locoregional control in DTC, based on review of literature and expert opinion of the authors. (1) EBRT is recommended for patients with gross residual or unresectable locoregional disease, except for patients <45 years old with limited gross disease that is radioactive iodine (RAI)‐avid. (2) EBRT should not be routinely used as adjuvant therapy after complete resection of gross disease. (3) After complete resection, EBRT may be considered in select patients >45 years old with high likelihood of microscopic residual disease and low likelihood of responding to RAI. (4) Cervical lymph node involvement alone should not be an indication for adjuvant EBRT. © 2015 Wiley Periodicals, Inc. Head Neck 38: 493–498, 2016